Propanc Biopharma, Common Stock Operating Margin
| PPCB Stock | USD 6.10 3.80 38.38% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess Propanc Biopharma,'s long-term financial health and intrinsic value.
Propanc |
Propanc Biopharma, Common Company Operating Margin Analysis
Propanc Biopharma,'s Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
| Competition |
Based on the recorded statements, Propanc Biopharma, Common has an Operating Margin of 0.0%. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The operating margin for all United States stocks is 100.0% lower than that of the firm.
Propanc Operating Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Propanc Biopharma,'s direct or indirect competition against its Operating Margin to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Propanc Biopharma, could also be used in its relative valuation, which is a method of valuing Propanc Biopharma, by comparing valuation metrics of similar companies.Propanc Biopharma, is currently under evaluation in operating margin category among its peers.
Propanc Fundamentals
| Return On Asset | -13.07 | |||
| Current Valuation | 1.53 M | |||
| Shares Outstanding | 1.76 B | |||
| Shares Owned By Insiders | 1.60 % | |||
| Price To Earning | (0.04) X | |||
| EBITDA | (2.14 M) | |||
| Net Income | (2.66 M) | |||
| Cash And Equivalents | 4.07 K | |||
| Total Debt | 1.1 M | |||
| Book Value Per Share | (0) X | |||
| Cash Flow From Operations | (1.44 M) | |||
| Earnings Per Share | (0.09) X | |||
| Target Price | 1.52 | |||
| Beta | 1.42 | |||
| Market Capitalization | 705.56 K | |||
| Total Asset | 81.65 K | |||
| Z Score | -85.8 | |||
| Net Asset | 81.65 K |
About Propanc Biopharma, Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Propanc Biopharma, Common's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Propanc Biopharma, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Propanc Biopharma, Common based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Propanc Pink Sheet
Propanc Biopharma, financial ratios help investors to determine whether Propanc Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Propanc with respect to the benefits of owning Propanc Biopharma, security.